Biosimilars Market Analysis

The global biosimilars market is segmented and analyzed for demand and supply by product type segment into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Amongst these segments, the recombinant non-glycosylated proteins segment garnered the highest market share in the year 2022, backed by the growing concern of rising incidences of diabetes along with the surge in the spread of diabetes worldwide. Furthermore, recombinant non-glycosylated proteins are used for the treatment of the diabetes, and it is predicted to boost the growth of the segment in the market. For instance, it was estimated that 1.5 million deaths were directly caused by diabetes worldwide, it was the 9th leading cause of death in 2019.

The global biosimilars market is also segmented and analyzed for demand and supply by application into hematology, oncology, and autoimmune diseases. Amongst these segments, the oncology segment garnered the highest market share owing to the rising number of cancer cases across the globe. Moreover, biosimilars have been created and approved to deliver efficient results in breast cancer treatment, colorectal cancer treatment, and other solid tumor treatments. Chemotherapy and other cancer therapies are combined with biosimilars to increase cancer patients' chances of survival and quality of life, and it is expected to increase the segment’s growth in the market. For instance, about 18 million people were suffering from cancer globally in 2020.

Our in-depth analysis of the global biosimilars market includes the following segments: